FDA issues EUA for Eli Lilly’ monoclonal antibody COVID-19 treatment
The Food and Drug Administration Nov. 10 issued an emergency use authorization for Eli Lilly and Company’s monoclonal antibody therapy, bamlanivimab.
The EUA authorizes the product’s use, but only in outpatient settings; additionally, it sets forth the type of patients eligible to receive the treatment, the drug’s storage requirements and a brief overview of how distribution will work.
Operation Warp Speed will begin to distribute nearly 80,000 vials of this therapy today, with most hospitals anticipated to receive their allocation tomorrow or Thursday.
Related News Articles
Blog
The RAND Corporation recently released the fifth iteration of its biannual hospital price report. The AHA has previously highlighted significant flaws with…
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
The Food and Drug Administration recently granted emergency use authorization for the first over-the-counter home antigen test to detect both flu and COVID-19…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…